Salud financiera de hoja de balance de Quince Therapeutics

Salud financiera controles de criterios 4/6

Quince Therapeutics tiene un patrimonio de los accionistas total de $44.9M y una deuda total de $14.9M, lo que sitúa su ratio deuda-patrimonio en 33.2%. Sus activos y pasivos totales son $126.5M y $81.6M respectivamente.

Información clave

33.2%

Ratio deuda-patrimonio

US$14.90m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$47.85m
Patrimonio	US$44.93m
Total pasivo	US$81.59m
Activos totales	US$126.52m

Actualizaciones recientes sobre salud financiera

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Nov 21

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

Dec 15

We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Aug 23

Recent updates

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 20

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Nov 21

Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Mar 10

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($51.7M) de QNCX superan a sus pasivos a corto plazo ($5.4M).

Pasivo a largo plazo: Los activos a corto plazo ($51.7M) de QNCX no cubren sus pasivos a largo plazo ($76.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: QNCX tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de QNCX ha crecido de 0% a 33.2% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: QNCX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: QNCX dispone de suficiente cash runway para 1.2 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 0.3% cada año.

Salud financiera de hoja de balance de Quince Therapeutics

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Quince Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Quince Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Quince Therapeutics Gets an Initial Compliance Period of 180 Calendar Days to Regain Compliance with the Minimum Bid Price Requirement

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Recent updates

New minor risk - Shareholder dilution

Quince Therapeutics Presents Safety Data from Prior Phase 3 Attest Clinical Trial At 53rd Child Neurology Society Annual Meeting

New minor risk - Profitability

CEO, Chief Medical Officer & Director recently bought US$107k worth of stock

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Quince Therapeutics, Inc. Announces the Online Publication of Data in the Lancet Neurology from Its Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Quince Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Quince Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer

Insufficient new directors

New minor risk - Shareholder dilution

Quince Therapeutics, Inc. Appoints Luca Benatti as Director

Quince Therapeutics, Inc. (NasdaqGS:QNCX) acquired EryDel S.p.A. for approximately $510 million.

Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug (Ind) Application for Its Lead Phase 3 Asset, Erydex

Quince Therapeutics Appoints Charles S. Ryan as President

Independent Chairman of the board recently bought US$108k worth of stock

Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023

CEO, President & Director recently bought US$99k worth of stock

New minor risk - Share price stability

Quince Therapeutics, Inc. (NasdaqGS:QNCX) agreed to acquire EryDel S.p.A. for approximately $490 million.

Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. (NasdaqGS:QNCX) for $10.5 million.

Price target increased by 56% to US$12.00

Quince Therapeutics Gets an Initial Compliance Period of 180 Calendar Days to Regain Compliance with the Minimum Bid Price Requirement

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Insufficient new directors

Insufficient new directors

Quince Therapeutics, Inc. Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

Price target increased to US$8.38

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Cortexyme to change name and ticker symbol next month

Cortexyme, Inc. Announces Resignation of Leslie Holsinger as Executive Vice President of Research and Development, Effective July 31, 2022

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 2000 Dynamic Index

Cortexyme, Inc. Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Cortexyme, Inc. Appoints June Bray to its Board of Directors

Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer

Cortexyme, Inc. (NasdaqGS:CRTX) acquired Novosteo Inc. from David Lamond and others for $19.8 million.

Dr. Dirk Thye and Philip Low to Join Cortexyme Board

Price target decreased to US$7.60

Cortexyme, Inc. Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of Its Phase 1 Clinical Trial of Cor588

Price target decreased to US$7.60

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

Cortexyme, Inc. Announces Executives Changes

Cortexyme, Inc. Receives Letter from the U.S. Food and Drug Administration, Placing Full Clinical Hold on Atuzaginstat’s (COR388) Investigational New Drug Application

Price target increased to US$44.00

Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

COO, CFO & Treasurer exercised options to buy US$387k worth of stock.

Cortexyme: A Challenging Path Forward

Cortexyme: Positive Lessons To Be Learned From Disappointing Results

Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease

COO, CFO & Treasurer exercised options and sold US$217k worth of stock

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021

Cortexyme: Alzheimer's Readout In November A Binary Event

Cortexyme, Inc. Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

Price target increased to US$97.71

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Price target increased to US$89.00

Price target increased to US$78.29

Cortexyme, Inc. Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021

COO, CFO & Treasurer exercised options and sold US$1.0m worth of stock

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 3000E Value Index